Kalvista Pharmaceuticals Inc (KALV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kalvista Pharmaceuticals Inc (KALV) has a cash flow conversion efficiency ratio of -1.923x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.68 Million) by net assets ($17.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kalvista Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Kalvista Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Kalvista Pharmaceuticals Inc debt and liabilities for a breakdown of total debt and financial obligations.
Kalvista Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kalvista Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hebei Huijin Electromechanical Co Ltd
SHE:300368
|
-0.047x |
|
Argus Shanghai Textile Chemicals Co Ltd
SHG:603790
|
0.021x |
|
Global Top E Commerce Co Ltd
SHE:002640
|
-0.326x |
|
Africa Oil Corp
TO:AOI
|
0.039x |
|
Jiangsu High Hope International Group Corp
SHG:600981
|
-0.062x |
|
Jaya Real Property Tbk
JK:JRPT
|
0.014x |
|
Oxford Lane Capital Corp
NASDAQ:OXLC
|
0.240x |
|
FastPartner AB (publ)
ST:FPAR-A
|
0.009x |
Annual Cash Flow Conversion Efficiency for Kalvista Pharmaceuticals Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Kalvista Pharmaceuticals Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see KALV stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $95.39 Million | $-152.91 Million | -1.603x | -271.10% |
| 2024-04-30 | $206.58 Million | $-89.23 Million | -0.432x | +7.58% |
| 2023-04-30 | $161.03 Million | $-75.26 Million | -0.467x | -10.72% |
| 2022-04-30 | $185.09 Million | $-78.13 Million | -0.422x | -259.85% |
| 2021-04-30 | $257.19 Million | $-30.17 Million | -0.117x | +78.08% |
| 2020-04-30 | $83.75 Million | $-44.82 Million | -0.535x | -42.35% |
| 2019-04-30 | $96.74 Million | $-36.37 Million | -0.376x | -197.03% |
| 2018-04-30 | $27.25 Million | $10.56 Million | 0.387x | +151.16% |
| 2017-04-30 | $31.33 Million | $-23.72 Million | -0.757x | -23.73% |
| 2016-04-30 | $21.50 Million | $-13.16 Million | -0.612x | -418.50% |
| 2016-03-31 | $43.07 Million | $-5.08 Million | -0.118x | +72.10% |
| 2015-12-31 | $49.31 Million | $-20.86 Million | -0.423x | -393.54% |
| 2015-04-30 | $-44.18 Million | $-6.37 Million | 0.144x | -94.08% |
| 2014-12-31 | $-4.62 Million | $-11.25 Million | 2.433x | +1588.23% |
| 2014-04-30 | $-33.71 Million | $-4.86 Million | 0.144x | +122.15% |
| 2013-04-30 | $-28.29 Million | $-1.83 Million | 0.065x | -- |
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which … Read more